MBX Biosciences, Inc.

Contributing Author

Recent Articles by MBX Biosciences, Inc.

Oct-20	MBX Biosciences to Participate in November Investor Conferences MBX GlobeNewswire
Sep-29	MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum MBX GlobeNewswire
Sep-24	MBX Biosciences Announces Pricing of Upsized Public Offering MBX GlobeNewswire
Sep-22	MBX Biosciences Announces Proposed Public Offering MBX GlobeNewswire
Sep-22	MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension MBX GlobeNewswire
Sep-19	MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22 MBX GlobeNewswire
Sep-04	MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity MBX GlobeNewswire
Aug-07	MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights MBX GlobeNewswire
Jun-23	MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development MBX GlobeNewswire
Jun-16	MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity MBX GlobeNewswire
Jun-10	MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions MBX GlobeNewswire
May-20	MBX Biosciences to Participate in June Investor Conferences MBX GlobeNewswire
May-12	MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights MBX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.